The US Food and Drug Administration (FDA) has approved roflumilast 0.3% cream for the topical treatment of plaque psoriasis, including psoriasis in intertriginous areas in patients aged 12 years and older.

Roflumilast is a selective inhibitor of phosphodiesterase 4 (PDE4) and is the first and only topical PDE4 inhibitor approved for psoriasis treatment. The high points of roflumilast cream are: one, it is a steroid-free cream and therefore is safe for long-term use. Secondly, it is effective in cases of difficult-to-treat intertriginous psoriasis. In clinical trials, topical roflumilast was shown to achieve rapid skin clearance and also reduce the associated itching. It is expected to be available on the market by the middle of the next month.

Dose and administration: Once daily application in mild, moderate, and severe plaque psoriasis with no limitations on duration of use

Adverse effects: Diarrhea, headache, insomnia, nausea, application-site pain, upper respiratory tract infections, urinary tract infections.

References

1. Topical roflumilast approved for psoriasis in adults and adolescents - Medscape - Jul 29, 2022.
2. https://www.arcutis.com/fda-approves-arcutis-zoryve-roflumilast-cream-0-3-for-the-treatment-of-plaque-psoriasis-in-individuals-age-12-and-older/.